Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 in fluenza virus vaccines administered to adults: Pooled analysis of 28 clinical trials

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 10, 2014, Pages 2942-2957

  Vaughn, David W ^a   Seifert, Harry ^b   Hepburn, Anne ^c   Dewe, Walthere ^a   Li, Ping ^b   Drame, Mamadou ^b   Cohet, Catherine ^a   Innis, Bruce L ^b   Fries, Louis F ^b,d  

^a GSK   (Belgium)

^b GLAXOSMITHKLINE   (United States)

^c GlaxoSmithKline Biologicals ^*  (Belgium)

^d NOVAVAX INC   (United States)

Author keywords

A(H1N1)pdm09 vaccine; H5N1 vaccine; Influenza A(H5N1); Pandemic influenza A(H1N1); Pooled analysis; Potential immune mediated disease; Safety

Indexed keywords

ARSENIC TRIOXIDE; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; PLACEBO; ALPHA TOCOPHEROL; ASO3B ADJUVANT; DRUG COMBINATION; POLYSORBATE; SQUALENE; VIRUS ANTIBODY;

ARTICLE; AUTOIMMUNE HEPATITIS; CELIAC DISEASE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG SAFETY; FACIAL NERVE PARALYSIS; GRAVES DISEASE; HUMAN; INCIDENCE; INFLUENZA A (H1N1); INFLUENZA A (H5N1); INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MULTIPLE SCLEROSIS; NEURITIS; OPTIC NEURITIS; PSORIASIS; RADICULITIS; RADICULOPATHY; RHEUMATIC POLYMYALGIA; RHEUMATOID ARTHRITIS; RISK FACTOR; THROMBOCYTOPENIA; ULCERATIVE COLITIS; UVEITIS; VACCINATION; ADOLESCENT; ADULT; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H5N1); INFLUENZA, HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; RISK; VIROLOGY; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ALPHA-TOCOPHEROL; ANTIBODIES, VIRAL; DRUG COMBINATIONS; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; POLYSORBATES; RISK; SQUALENE; VACCINATION; YOUNG ADULT;

EID: 84921522632     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/21645515.2014.972149     Document Type: Article

References (85)

1. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature 2006; 442:448-52; PMID:16642006; http://dx.doi.org/10.1038/nature04795
2. Germann TC, Kadau K, Longini IM Jr, Macken CA. Mitigation strategies for pandemic influenza in the United States. Proc Natl Acad Sci USA 2006; 103:5935-40; PMID:16585506; http://dx.doi.org/10.1073/pnas.0601266103
3. Leroux-Roels I, Borkowski A, Vanwolleghem T, Drame M, Clement F, Hons E, Devaster JM, Leroux-Roels G. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580-9; PMID:17707753; http://dx.doi.org/10.1016/S0140-6736(07)61297-5
4. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010; 28:1740-5; PMID:20034605; http://dx.doi.org/10.1016/j.vaccine.2009.12.014
5. Leroux-Roels I, Bernhard R, Gerard P, Drame M, Hanon E, Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 2008; 3:e1665; PMID:18301743; http://dx.doi.org/10.1371/journal.pone.0001665
6. Roman F, Clement F, Dewe W, Walravens K, Maes C, Willekens J, De Boever F, Hanon E, Leroux-Roels G. Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin Vaccine Immunol 2011; 18:835-43; PMID:21450978; http://dx.doi.org/10.1128/CVI.00480-10
7. Yang WH, Dionne M, Kyle M, Aggarwal N, Li P, Madariaga M, Godeaux O, Vaughn DW. Long-term immunogenicity of an AS03-adjuvanted influenza A (H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial. Vaccine 2013; 31:4389-97; PMID:23856331; http://dx.doi.org/10.1016/j.vaccine.2013.07.007
8. Poder A, Simurka P, Li P, Roy-Ghanta S, Vaughn D. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age. Vaccine 2014; 32:1121-9; PMID:24252703; http://dx.doi.org/10.1016/j.vaccine.2013.11.031
9. Ferguson M, Risi G, Davis M, Sheldon E, Baron M, Li P, Madariaga M, Fries L, Godeaux O, Vaughn D. Safety and Long-term Humoral Immune Response in Adults After Vaccination With an H1N1 2009 Pandemic Influenza Vaccine With or Without AS03 Adjuvant. J Infect Dis 2012; 205:733-44; PMID: 22315336; http://dx.doi.org/10.1093/infdis/jir641
10. Fedson DS. Preparing for pandemic vaccination: an international policy agenda for vaccine development. J Public Health Policy 2005; 26:4-29; PMID:15906873; http://dx.doi.org/10.1057/palgrave.jphp.3200008
11. Rumke HC, Bayas JM, de Juanes JR, Caso C, Richardus JH, Campins M, Rombo L, Duval X, Romanenko V, Schwarz TF, et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008; 26:2378-88; PMID:18407382; http://dx.doi.org/10.1016/j.vaccine.2008.02.068
12. Langley JM, Frenette L, Ferguson L, Riff D, Sheldon E, Risi G, Johnson C, Li P, Kenney R, Innis B, et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis 2010; 201:1644-53; PMID:20423222; http://dx.doi.org/10.1086/652701
13. Skowronski DM, Janjua NZ, De Serres G, Hottes TS, Dickinson JA, Crowcroft N, Kwindt TL, Tang P, Charest H, Fonseca K, et al. Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ 2011; 342:c7297; PMID:21292718; http://dx.doi.org/10.1136/bmj.c7297
14. Van Buynder PG, Dhaliwal JK, Van Buynder JL, Couturier C, Minville-LeBlanc M, Garceau R, Tremblay F. Protective effect of single-dose adjuvanted pandemic influenza vaccine in children. Influenza Other Respir Viruses 2010; 4:171-178; PMID:20629771; http://dx.doi.org/10.1111/j.1750-2659.2010.00146.x
15. Wichmann O, Stöcker P, Poggensee G, Altmann D, Walter D, Hellenbrand W, Krause G, Eckmanns T. Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010. Euro Surveill 2010; 15:pii=19561; PMID:20460094
16. Nolan T, Roy-Ghanta S, Montellano M, Weckx L, Ulloa-Gutierrez R, Lazcano-Ponce E, Kerdpanich P, Safadi M, Cruz-Valdez A, Litao S, et al. Relative efficacy of AS03-adjuvanted pandemic H1N1 influenza vaccine in children: results of a controlled, randomized efficacy trial. J Infect Dis 2014 [in press]
17. European Medicines Agency. Assessment report for Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Public-assessment-report/human/001206/WC500049547.pdf. Accessed 14 Feb 2014.
18. Product information leaflet AREPANRIX™ H1N1 AS03-Adjuvanted H1N1 Pandemic Influenza Vaccine. Available at: http://www.hc-sc.gc.ca/dhp-mps/alt-formats/pdf/prodpharma/legislation/interimorders-arretesurgence/prodinfo-vaccin-eng.pdf. Accessed 14 Feb 2014.
19. European Medicines Agency. CHMP Recommendations for the Pharmacovigilance Plan as part of the Risk Management Plan to be submitted with the Marketing Authorisation Application for a Pandemic Influenza Vaccine. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Report/2010/01/WC500051739.pdf. Accessed 14 Feb 2014
20. Sobel JD. Vulvovaginal candidosis. Lancet 2007; 369:1961-71; PMID:17560449; http://dx.doi.org/10.1016/S0140-6736(07)60917-9
21. Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis 2001; 183 (Suppl 1):S1-4; PMID:11171002; http://dx.doi.org/10.1086/318850
22. Toxicology Review of Influenza A (H5N1) virus monovalent vaccine, adjuvanted. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM379021.pdf. Accessed 10 Mar 2014
23. European Medicines Agency. CHMP assessment report for Pandemrix. London, 24 September 2009. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Assessment-Report---Variation/human/000832/WC500095422.pdf. Accessed 10 Mar 2014
24. Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouahabi A, Harvengt P, Carlsen H, et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011; 29:2461-73; PMID:21256188; http://dx.doi.org/10.1016/j.vaccine.2011.01.011
25. Black S, Eskola J, Siegrist CA, Halsey N, Macdonald N, Law B, Miller E, Andrews N, Stowe J, Salmon D, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 2009; 374:2115-22; PMID:19880172; http://dx.doi.org/10.1016/S0140-6736(09)61877-8
26. Brandenburg NA, Annegers JF. Incidence and risk factors for Bell's palsy in Laredo, Texas: 1974-1982. Neuroepidemiology 1993; 12:313-25; PMID:8309506; http://dx.doi.org/10.1159/000110333
27. Campbell KE, Brundage JF. Effects of climate, latitude, and season on the incidence of Bell's palsy in the US Armed Forces, October 1997 to September 1999. Am J Epidemiol 2002; 156:32-9; PMID:12076886; http://dx.doi.org/10.1093/aje/kwf009
28. deDiego JI, Prim MP, Madero R, Gavilan J. Seasonal patterns of idiopathioc facial paralysis: a 16-year study. Otolaryngol Head Neck Surg 1999; 120:269-71; PMID:9949364; http://dx.doi.org/10.1016/S0194-5998(99)70418-3
29. Katusic SK, Beard CM, Wiederholt WC, Bergstralh EJ, Kurland LT. Incidence, clinical features, and prognosis in Bell's palsy, Rochester, Minnesota, 1968-1982. Ann Neurol 1986; 20:622-7; PMID:3789675; http://dx.doi.org/10.1002/ana.410200511
30. Kurz X, Domergue F, Slattery J, Segec A, Szmigiel A, Hidalgo-Simon A. Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilance. Vaccine 2011; 29:4378-87; PMID:21501644; http://dx.doi.org/10.1016/j.vaccine.2011.04.005
31. Morris AM, Deeks SL, Hill MD, Midroni G, Goldstein WC, Mazzulli T, Davidson R, Squires SG, Marrie T, McGeer A, et al. Annualized incidence and spectrum of illness from an outbreak investigation of Bell's palsy. Neuroepidemiology 2002; 21:255-61; PMID:12207155; http://dx.doi.org/10.1159/000065645
32. Cimmino MA, Zaccaria A. Epidemiology of polymyalgia rheumatica. Clin Exp Rheumatol 2000; 18:S9-11; PMID:10948749
33. Doran MF, Crowson CS, O'Fallon WM, Hunder GG, Gabriel SE. Trends in the incidence of polymyalgia rheumatica over a 30 year period in Olmsted County, Minnesota, USA. J Rheumatol 2002; 29:1694-7; PMID:12180732
34. Smeeth L, Cook C, Hall AJ. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990-2001. Ann Rheum Dis 2006; 65:1093-8; PMID:16414971; http://dx.doi.org/10.1136/ard.2005.046912
35. Huerta C, Rivero E, Rodriguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007; 143:1559-65; PMID:18087008
36. Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Maradit Kremers H. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. J Am Acad Dermatol 2009; 60:394-401; PMID:19231638; http://dx.doi.org/10.1016/j.jaad.2008.10.062
37. Abraham-Nordling M, Torring O, Lantz M, Hallengren B, Ohrling H, Lundell G, Calissendorff J, Jorneskog G, Wallin G. Incidence of hyperthyroidism in Stockholm, Sweden, 2003-2005. Eur J Endocrinol 2008; 158:823-7; PMID:18505903; http://dx.doi.org/10.1530/EJE-07-0877
38. Berglund J, Ericsson UB, Hallengren B. Increased incidence of thyrotoxicosis in Malmo during the years 1988-1990 as compared to the years 1970-1974. J Intern Med 1996; 239:57-62; PMID:8551201; http://dx.doi.org/10.1046/j.1365-2796.1996.415757000.x
39. Brownlie BE, Wells JE. The epidemiology of thyrotoxicosis in New Zealand: incidence and geographical distribution in north Canterbury, 1983-1985. Clin Endocrinol (Oxf) 1990; 33:249-59; PMID:2225482; http://dx.doi.org/10.1111/j.1365-2265.1990.tb00489.x
40. Galofre JC, Garcia-Mayor RV, Fluiters E, Fernandez-Calvet L, Rego A, Paramo C, Andrade MA. Incidence of different forms of thyroid dysfunction and its degrees in an iodine sufficient area. Thyroidology 1994; 6:49-54; PMID:7536450
41. Klein NP, Ray P, Carpenter D, Hansen J, Lewis E, Fireman B, Black S, Galindo C, Schmidt J, Baxter R. Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine 2010; 28:1062-8; PMID:19896453; http://dx.doi.org/10.1016/j.vaccine.2009.10.115
42. Modrego PJ, Pina MA. Trends in prevalence and incidence of multiple sclerosis in Bajo Aragon, Spain. J Neurol Sci 2003; 216:89-93; PMID:14607307; http://dx.doi.org/10.1016/j.jns.2003.07.007
43. Cook B, Oxner R, Chapman B, Whitehead M, Burt M. A thirty-year (1970-1999) study of coeliac disease in the Canterbury region of New Zealand. N Z Med J 2004; 117:U772; PMID:15014561
44. Murray JA, Van Dyke C, Plevak MF, Dierkhising RA, Zinsmeister AR, Melton LJ 3rd. Trends in the identification and clinical features of celiac disease in a North American community, 1950-2001. Clin Gastroenterol Hepatol 2003; 1:19-27; PMID:15017513; http://dx.doi.org/10.1053/jcgh.2003.50004
45. Radhakrishan K, Litchy WJ, O'Fallon WM, Kurland LT. Epidemiology of cervical radiculopathy: a population-based study from Rochester, Minnesota, 1976-1990. Brain 1994; 117:325-35; PMID:8186959; http://dx.doi.org/10.1093/brain/117.2.325
46. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011; 140:1785-94; PMID:21530745; http://dx.doi.org/10.1053/j.gastro.2011.01.055
47. Loftus EV Jr, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am 2002; 31:1-20; PMID:12122726; http://dx.doi.org/10.1016/S0889-8553(01)00002-4
48. Carbonell J, Cobo T, Balsa A, Descalzo MA, Carmona L, SERAP Study Group. The incidence of rheumatoid arthritis in Spain: results from a nationwide primary care registry. Rheumatology (Oxford) 2008; 47:1088-92; PMID:18511475; http://dx.doi.org/10.1093/rheumatology/ken205
49. Pedersen JK, Kjaer NK, Svendsen AJ, Horslev-Petersen K. Incidence of rheumatoid arthritis from 1995 to 2001: impact of ascertainment from multiple sources. Rheumatol Int 2009; 29:411-5; PMID:18853167; http://dx.doi.org/10.1007/s00296-008-0713-6
50. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 2004; 111:491-500; PMID:15019324; http://dx.doi.org/10.1016/j.ophtha.2003.06.014
51. Zhou W, Pool V, DeStefano F, Iskander JK, Haber P, Chen RT; VAERS Working Group. A potential signal of Bell's palsy after parenteral influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS) - United States, 1991-2001. Pharmacoepidemiol Drug Saf 2004; 13:505-10; PMID:15317028; http://dx.doi.org/10.1002/pds.998
52. Tavares Da Silva F, De Keyser F, Lambert PH, Robinson WH, Westhovens R, Sindic C. Optimal approaches to data collection and analysis of potential immune mediated disorders in clinical trials of new vaccines. Vaccine. 2013; 31:1870-6; PMID:23391600; http://dx.doi.org/10.1016/j.vaccine.2013.01.042
53. Nazareth I, Tavares F, Rosillon D, Haguinet F, Bauchau V. Safety of AS03-adjuvanted split-virion H1N1 (2009) pandemic influenza vaccine: a prospective cohort study. BMJ Open 2013; 3:e001912; PMID:23388195; http://dx.doi.org/10.1136/bmjopen-2012-001912
54. Bardage C, Persson I, Ortqvist A, Bergman U, Ludvigsson JF, Granath F. Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden. BMJ 2011; 343:d5956; PMID:21994316; http://dx.doi.org/10.1136/bmj.d5956
55. Persson I, Granath F, Askling J, Ludvigsson JF, Olsson T, Feltelius N. Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up. J Intern Med 2014; 275:172-90; PMID:24134219; http://dx.doi.org/10.1111/joim.12150
56. Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, Sundman J, Himanen SL, Hublin C, Julkunen I, Olsen P, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 2012; 7: e33536; PMID:22470453; http://dx.doi.org/10.1371/journal.pone.0033536
57. Jokinen J, Nohynek H, Honkanen J, Vaarala O, Partinen M, Hublin C, Kilpi T. Association between the pandemic vaccine and narcolepsy in adults. Cohort study based on confirmed register data. THL 2013. Available at: http://www.julkari.fi/bitstream/handle/10024/104482/URN-ISBN-978-952-245-921-3.pdf?sequence=1. Accessed 14 Feb 2014
58. Medical Products Agency (MPA) - Sweden. Occurrence of narcolepsy with cataplexy among children and adolescents in relation to the H1N1 pandemic and Pandemrix vaccinations - Results of a case inventory study by the MPA in Sweden during 2009-2010. Thirty June 2011. Available at: http://www.lakemedelsverket.se/upload/nyheter/2011/Fallinventeringsrapport-pandermrix-110630.pdf. Accessed 14 Feb 2014.
59. Persson I, Granath F, Askling J, Ludvigsson JF, Olsson T, Feltelius N. Risks of neurological and immune-related diseases, including narcolepsy, after vaccination with Pandemrix: a population- and registry-based cohort study with over 2 years of follow-up. J Intern Med 2014;275:172-90; PMID:24134219; http://dx.doi.org/10.1111/joim.12150
60. Szakacs A, Darin N, Hallbook T. Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. Neurology 2013;80:1315-21; PMID:23486871; http://dx.doi.org/10.1212/WNL.0b013e31828ab26f
61. Department of Health (Ireland). Investigation of an increase in the incidence of narcolepsy in children and adolescents in 2009 and 2010. Final Report of National Narcolepsy Study Steering Committee (2012). Available at: http://www.dohc.ie/publications/pdf/Final-Report-of-National-Narcolepsy-Study-Steering-Committee.pdf?direct=1. Accessed 14 Feb 2014
62. Dauvilliers Y, Arnulf I, Lecendreux M, Monaca Charley C, Franco P, Drouot X, d'Ortho MP, Launois S, Lignot S, Bourgin P, et al. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain 2013; 136:2486-96; PMID:23884811; http://dx.doi.org/10.1093/brain/awt187
63. European Center for Disease Prevention and Control Infections, Vaccinations and Narcolepsy Background rates and Case-control Study, Final Study Report VAESCO-Narcolepsy v1.9.7 ECDC Technical report, Oct. 2012. Narcolepsy in association with pandemic influenza vaccination (a multi-country European epidemiological investigation). Stockholm: ECDC; September 2012. Available at: http://ecdc.europa.eu/en/publications/Publications/Vaesco%20report%20FINAL%20with%20cover.pdf. Accessed 14 Feb 2014
64. Miller E, Andrews N, Stellitano L, Stowe J, Winstone AM, Shneerson J, Verity C. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 2013; 346:f794; PMID:23444425; http://dx.doi.org/10.1136/bmj.f794
65. Heier MS, Gautvik KM, Wannag E, Bronder KH, Midtlyng E, Kamaleri Y, Storsaeter J. Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A. Sleep Med 2013; 14:867-71; PMID:23773727; http://dx.doi.org/10.1016/j.sleep.2013.03.020
66. Langley JM, Risi G, Caldwell M, Gilderman L, Berwald B, Fogarty C, Poling T, Riff D, Baron M, Frenette L, et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis 2011; 203:1729-38; PMID: 21606531; http://dx.doi.org/10.1093/infdis/jir172
67. Lieu TA, Kulldorff M, Davis RL, Lewis EM, Weintraub E, Yih K, Yin R, Brown JS, Platt R; Vaccine Safety Datalink Rapid Cycle Analysis Team. Real-time vaccine safety surveillance for the early detection of adverse events. Med Care 2007; 45:S89-95; PMID:17909389; http://dx.doi.org/10.1097/MLR.0b013e3180616c0a
68. Breslow NE, Day W. Statistical Methods in Cancer research: the analysis of case-control studies. Oxford: Oxford University Press; 1980.;
69. Langley J, Frenette L, Jeanfreau R, Chu L, McNeil S, Halperin S, Dramé M, Fries L, Vaughn D. Immunogenicity of a Heterologous H5N1 Booster Vaccine 6 and 18 Months after Primary Vaccination in Adults. 49th Annual Meeting of the Infectious Diseases Society of America -; 2011 October 20-23, Boston.
70. Risi G, Frenette L, Langley JM, Li P, Riff D, Sheldon E, Vaughn DW, Fries L. Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 months. Vaccine 2011; 29:6408-18; PMID:21554915; http://dx.doi.org/10.1016/j.vaccine.2011.04.072
71. Chu DW, Hwang SJ, Lim FS, Oh HM, Thongcharoen P, Yang PC, Bock HL, Dramé M, Gillard P, Hutagalung Y, et al. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine 2009; 27:7428-35; PMID:19683087; http://dx.doi.org/10.1016/j.vaccine.2009.07.102
72. Heijmans S, De Meulemeester M, Reynders P, Giet D, Demanet E, Devresse PY, Icardi G, Dramé M, Roman F, Gillard P. Immunogenicity profile of a 3.75-μg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial. J Infect Dis 2011; 203:1054-62; PMID: 21450995; http://dx.doi.org/10.1093/infdis/jiq174
73. Langley JM, Frenette L, Chu L, McNeil S, Halperin S, Li P, Vaughn D. A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine. BMC Infect Dis. 2012; 12:279; PMID:23110320; http://dx.doi.org/10.1186/1471-2334-12-279
74. Lasko B, Reich D, Madan A, Roman F, Li P, Vaughn D. Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03(A)-adjuvanted vaccination in adults. J Infect Dis 2011; 204:574-81; PMID:21791660; http://dx.doi.org/10.1093/infdis/jir328
75. Nagai H, Ikematsu H, Tenjinbaru K, Maeda A, Dramé M, Roman FP. A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults. BMC Infect Dis 2010; 10:338; PMID:21108818; http://dx.doi.org/10.1186/1471-2334-10-338
76. Schwarz TF, Horacek T, Knuf M, Damman HG, Roman F, Dramé M, Gillard P, Jilg W. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 2009; 27:6284-90; PMID:19856521; http://dx.doi.org/10.1016/j.vaccine.2009.01.040
77. Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Dramé M, Gillard P, van der Most R, Van Mechelen M, Hanon E, et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 2010; 28:849-57; PMID:19835828; http://dx.doi.org/10.1016/j.vaccine.2009.10.017
78. Gillard P, Chu DW, Hwang SJ, Yang PC, Thongcharoen P, Lim FS, Dramé M, Walravens K, Roman F. Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults. BMC Infect Dis 2014; 14:142; PMID:24628789; http://dx.doi.org/10.1186/1471-2334-14-142
79. Yang PC, Yu CJ, Chang SC, Hsieh SM, Drame M, Walravens K, Roman F, Gillard P. Safety and immunogenicity of a split-virion AS03A-adjuvanted A/Indonesia/05/2005 (H5N1) vaccine in Taiwanese adults. J Formos Med Assoc 2012; 111:333-9; PMID:22748624; http://dx.doi.org/10.1016/j.jfma.2011.02.006
80. Ikematsu H, Nagai H, Kawashima M, Kawakami Y, Tenjinbaru K, Maeda A, Li P, Gillard P, Roman F. Immunogenicity and safety of a novel AS03(A)-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan. Hum Vaccin 2010; 6:888-93; PMID:20980795; http://dx.doi.org/10.4161/hv.6.11.12851
81. Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis 2010; 51:668-77; PMID:20687838; http://dx.doi.org/10.1086/655830
82. Launay O, Duval X, Fitoussi S, Jilg W, Kerdpanich A, Montellano M, Schwarz TF, Watanveerade V, Wenzel JJ, Zalcman G, et al. Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials. BMC Infect Dis 2013; 13:1-11; PMID:23280237; http://dx.doi.org/10.1186/1471-2334-13-435
83. Peeters M, Regner S, Vaman T, Devaster JM, Rombo L. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials. Vaccine 2012; 30:6483-91; PMID:22885014; http://dx.doi.org/10.1016/j.vaccine.2012.07.081
84. Duval X, Caplanusi A, Laurichesse H, Deplanque D, Loulergue P, Vaman T, Launay O, Gillard P. Flexibility of interval between vaccinations with AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18-60 and >60 ears: a randomized trial. BMC Infect Dis 2012; 12:162; PMID:22824474; http://dx.doi.org/10.1186/1471-2334-12-162
85. Yong M, Schoonen WM, Li L, Kanas G, Coalson J, Mowat F, Fryzek J, Kaye JA. Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database. Br J Haematol 2010; 149:855-64; PMID:20377590; http://dx.doi.org/10.1111/j.1365-2141.2010.08176.x